Takeda expands its rare diseases portfolio in India with the launch of Adynovate

Adynovate in combination with MYPKFIT®, FDA approved application offers personalised and interactive prophylaxis treatment option that enables both healthcare professionals (HCPs) and patients in real-time monitoring of factor VIII levels from their homes on phone

Takeda Pharmaceutical expands its rare diseases portfolio in India with the launch of Adynovate, an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for hemophilia A patients.

Adynovate in combination with MYPKFIT®, FDA approved application offers personalised and interactive prophylaxis treatment option that enables both healthcare professionals (HCPs) and patients in real-time monitoring of factor VIII levels from their homes on phone. Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low, and reminds them when their infusions are due, thereby providing excellent prophylactic coverage.

Commenting on the benefits of prophylaxis for hemophilia A patients, Dr Sandeep Arora, Head of Medical Affairs and Patient Services – India, Takeda said, “Individuals with severe hemophilia A have recurrent hemarthrosis, fragmentation of joint cartilage, bone destruction, and crippling which can be effectively reduced through prophylaxis as opposed to on-demand therapy. Studies show that an innovative extended half-life, Adynovate, helps patients to reduce dosing and infusion frequency thereby improving treatment adherence while providing personalized prophylactic coverage. Adynovate has been tested in comprehensive global clinical program demonstrating favorable safety and efficacy results that offer effective bleed resolution, better joint health, and almost ZERO spontaneous bleeds in majority.”

Administered in three steps with BAXJECT III system, Adynovate eliminates the need to disinfect the vial, as vials are already assembled in the system housing. It can be stored at room temperature not to exceed 30°C (86°F) for a period of up to 3 months not to exceed the expiration date thereby easing the handling and storing process.

 

HemophiliaHemophilia Arare diseasesTakeda
Comments (0)
Add Comment